Moderna wins patent lawsuit against BioNTech/Pfizer

German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation,
Pfizer, BioNTech notch US win—and loss in Germany—amid high-stakes patent fight with Moderna
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in | Moderna sued Pfizer and BioNTech over three patents protecting its COVID-19 work back in 2022.
Moderna Scores Legal Victory Over Pfizer, BioNTech in Patent Dispute
MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and BioNTech (BNTX, Financial). A Dusseldorf cour
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
IPWatchdog2d
Moderna COVID Vaccine Technology Struck Down by PTAB
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...
Health Rounds: Roche/BioNTech experimental vaccine shows early promise in pancreatic cancer
Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...
SVB Wealth LLC Buys Shares of 1,788 BioNTech SE (NASDAQ:BNTX)
SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
U.S. FDA places BioNTech's malaria vaccine study on clinical hold
BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...
BNTX Insider Trade Alert! Co-Founder and CEO Sells BioNTech Stock Worth $119M
Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...
BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...